Life Science & Biotech

Report: Roche mulls sale of blood-glucose monitor business

May 17, 2013
J.K. Wall
Roche Diagnostics Corp. is considering a sale of its blood-glucose meter business, a move that would cast uncertainty over the nearly 1,000 people working for its diabetes business in Indianapolis.
More

PANEL: Life sciences will see radically different futureRestricted Content

May 17, 2013
IBJ convened a panel of experts at its Life Sciences Power Breakfast on May 10 to talk about the industry issues of venture capital, digital health innovations and research university entrepreneurship.

Panel members included Kristin Eilenberg, CEO, Lodestone Logic, Infuse Accelerator; Philip S. Low, Purdue University professor of chemistry, founder and chief science officer at Endocyte Inc. and On Target Laboratories LLC; R. Matthew Neff, president, CHV Capital Inc.; Brian Stemme, project director; BioCrossroads; Brian S. Williams, director, Global Healthcare Strategy, PricewaterhouseCoopers International Ltd.; and Raul Zaveleta, CEO, Indigo BioSystems Inc.

The following is an unedited transcript of the discussion.

More

New seed fund aims to make Indiana a hotbed for digital health startupsRestricted Content

May 4, 2013
J.K. Wall
Infuse Accelerator hopes to make early-stage investments in 12 to 15 companies a year.
More

Lilly suing J&J for patent rights in Alzheimer's drug race

April 25, 2013
Bloomberg News
Eli Lilly and Co. is seeking to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay availability of a potential treatment for Alzheimer’s disease.
More

Dow AgroSciences grows sales, earnings to new heights

April 25, 2013
Mason King, Bloomberg News
Record sales for seeds and new crop protection products helped boost revenue 14 percent at Indianapolis-based Dow AgroSciences LLC in its new fiscal year.
More

Lilly seeks $30.6M in tax breaks on downtown projects

April 15, 2013
Mason King
Indianapolis development officials on Wednesday will weigh the 10-year requests from the pharmaceuticals giant related to a new manufacturing plant and improvements to existing operations downtown.
More

IU medical school's push to launch startups bears fruitRestricted Content

April 13, 2013
J.K. Wall
The Indiana University School of Medicine has launched 12 companies in the past 18 months—a burst of startup activity the school has never seen before.
More

Expected revenue slump spurs Lilly to cut sales force

April 11, 2013
J.K. Wall
The Indianapolis pharmaceuticals giant said Thursday that it would lay off hundreds of U.S. sales reps, as it prepares for the loss of patent protection on two of its best-selling drugs.
More

City to buy key parcel for 16th Street tech corridorRestricted Content

April 6, 2013
Scott Olson
The city of Indianapolis is poised to pay Citizens Energy Group $6.5 million to buy a key parcel of real estate it’s targeting as the centerpiece of its ambitious 16 Tech project.
More

Lilly pulls back from proposals lowering takeover barriersRestricted Content

April 6, 2013
Greg Andrews
Fortunately, a Lilly takeover looks less likely today than it has in a long time—for both obvious and more subtle reasons.
More

Lilly to spend $180M doubling size of Indy plant

April 2, 2013
The new investment will bring the plant's total price tag to $320 million as the pharmaceutical giant seeks to increase production of insulin and related products.
More

Sherry Labs snapped up by Netherlands corporation

April 1, 2013
Jeff Newman
The materials-testing business with nearly 300 employees has been acquired by Element Materials Technology. Sherry had been owned by a group of well-connected central Indiana businessmen.
More

Profits at center of biosimilars debate

March 18, 2013
J.K. Wall
House Bill 1315, which is scheduled for a Senate floor hearing on Monday, would require pharmacists to check with a patient’s physician before automatically substituting a generic version of a biotech drug for a brand-name version.
More

Medical device maker moving to Noblesville, adding jobs

March 12, 2013
Fishers-based Nexxt Spine LLC, a manufacturer of spinal implants, is consolidating operations and moving its headquarters and manufacturing facility to Noblesville.
More

Q&A

March 11, 2013
J.K. Wall
Mike Sherman, the chief financial officer at West Lafayette-based Endocyte Inc., talked about how the drug firm’s funding partnership with New Jersey-based Merck & Co. Inc. has helped accelerate development of the company’s pipeline, which is branching out into drugs to treat cancers of the lung, prostate and breast.
More

Lilly sues Genentech to invalidate Erbitux-related patents

March 2, 2013
Bloomberg News
Eli Lilly and Co. has sued Roche Holding AG’s Genentech unit, asking a court to invalidate patents used to make treatments for cancer and autoimmune diseases.
More

Dow AgroSciences wins bid to overturn pesticide guidelines

February 21, 2013
Bloomberg News
Indianapolis-based Dow Agrosciences LLC and two other pesticide makers won a bid to overturn U.S. National Marine Fisheries Service proposals to protect salmon when an appeals court found the agency’s decision “arbitrary and capricious.”
More

Lilly to expand partnership with diagnostic firm

February 14, 2013
 IBJ Staff and Associated Press
Diagnostic products maker Qiagen NV said Wednesday that it will work with Eli Lilly and Co. to develop new tests that could identify patients who could be helped by Lilly's drugs.
More

'12 worst year for life sciences since 1990s

February 11, 2013
J.K. Wall
To understand why Indiana’s life sciences entrepreneurs are frustrated with the flow of venture capital, look no further than this statistic from a recent PricewaterhouseCoopers report: 2012 was the slowest year for first-time life sciences investment since 1995.
More

Indiana officials look to boost agriculture research

February 3, 2013
Associated Press
The state's agriculture department under new Gov. Mike Pence is planning a push into the science behind food production by trying to build a network of university and commercial researchers for what's being called an Agriculture Innovation Corridor.
More

Health care startups hungry for fundsRestricted Content

February 2, 2013
J.K. Wall
Frustrated by up-and-down state funding for startup life sciences companies, industry leaders are talking up a plan to create a dedicated funding stream that could total $30 million a year.
More

Zimmer's earnings slip, but beat expectations

January 31, 2013
 IBJ Staff
Fourth-quarter profit fell 2 percent at Zimmer Holdings Inc. due to large accounting charges, but still beat the estimates of Wall Street analysts.
More

BioCrossroads: Life sciences a $50B industry in Indiana

January 22, 2013
J.K. Wall
The life sciences industry in Indiana employs 55,500 workers paying average wages of more than $88,500 per year, according to new figures released Tuesday by Indianapolis-based life sciences development group BioCrossroads.
More

Pence wants $1.5M a year for life sciences institute

January 21, 2013
J.K. Wall
The Indiana Applied Research Enterprise already has received support from John Lechleiter, CEO of Indianapolis-based Eli Lilly and Co., as a place for collaboration between academic and industrial scientists.
More

Former state ag director joins Dow AgroSciences

January 21, 2013
Joseph Kelsay, who had served as director of Indiana's Department of Agriculture since 2009, is joining Dow AgroSciences' government affairs team as senior manager of biotechnology affairs.
More
Page  << 1 2 3 4 5 6 7 8 9 10 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. How much you wanna bet, that 70% of the jobs created there (after construction) are minimum wage? And Harvey is correct, the vast majority of residents in this project will drive to their jobs, and to think otherwise, is like Harvey says, a pipe dream. Someone working at a restaurant or retail store will not be able to afford living there. What ever happened to people who wanted to build buildings, paying for it themselves? Not a fan of these tax deals.

  2. Uh, no GeorgeP. The project is supposed to bring on 1,000 jobs and those people along with the people that will be living in the new residential will be driving to their jobs. The walkable stuff is a pipe dream. Besides, walkable is defined as having all daily necessities within 1/2 mile. That's not the case here. Never will be.

  3. Brad is on to something there. The merger of the Formula E and IndyCar Series would give IndyCar access to International markets and Formula E access the Indianapolis 500, not to mention some other events in the USA. Maybe after 2016 but before the new Dallara is rolled out for 2018. This give IndyCar two more seasons to run the DW12 and Formula E to get charged up, pun intended. Then shock the racing world, pun intended, but making the 101st Indianapolis 500 a stellar, groundbreaking event: The first all-electric Indy 500, and use that platform to promote the future of the sport.

  4. No, HarveyF, the exact opposite. Greater density and closeness to retail and everyday necessities reduces traffic. When one has to drive miles for necessities, all those cars are on the roads for many miles. When reasonable density is built, low rise in this case, in the middle of a thriving retail area, one has to drive far less, actually reducing the number of cars on the road.

  5. The Indy Star announced today the appointment of a new Beverage Reporter! So instead of insightful reports on Indy pro sports and Indiana college teams, you now get to read stories about the 432nd new brewery open or some obscure Hoosier winery winning a county fair blue ribbon. Yep, that's the coverage we Star readers crave. Not.

ADVERTISEMENT